Stock events for Foghorn Therapeutics, Inc. (FHTX)
In the past six months, Foghorn Therapeutics participated in investor conferences, including the Guggenheim Emerging Outlook: Biotech Summit and the Evercore Healthcare Conference. Ryan Maynard was appointed as the new CFO in February 2026. The company closed a $50 million registered direct financing in January 2026 and provided a Third Quarter 2025 financial and corporate update in November 2025. The stock has seen a return of +7.4% over the last six months.
Demand Seasonality affecting Foghorn Therapeutics, Inc.’s stock price
Demand seasonality is not directly applicable to Foghorn Therapeutics' products as they are still in development. Demand for future therapies will be driven by clinical trials, regulatory approvals, and market adoption rather than seasonal trends. There is information regarding seasonal returns for the FHTX stock, which highlights recurring trends in asset performance over specific months of the year, but such historical stock performance patterns do not necessarily predict future results.
Overview of Foghorn Therapeutics, Inc.’s business
Foghorn Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicine therapeutics that target genetically determined dependencies within the chromatin regulatory system in oncology. The company utilizes its proprietary "Gene Traffic Control" platform to identify and validate potential drug targets. Its product candidates, primarily in oncology, include FHD-286 for metastatic uveal melanoma and relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome; FHD-609 for synovial sarcoma; and FHD-909 for SMARCA4-deficient cancers, being developed with Eli Lilly and Company. The company is also developing selective modulators for BRM and ARID1B for various cancers.
FHTX’s Geographic footprint
Foghorn Therapeutics Inc. is headquartered in Cambridge, Massachusetts, and was incorporated in Delaware. Its primary operations and focus are within the United States.
FHTX Corporate Image Assessment
Foghorn Therapeutics has maintained a positive brand reputation among analysts, with a consensus "Buy" rating based on 9 ratings and a consensus price target of $11.13. The company's participation in investor and healthcare conferences contributes to its visibility. There is no information available detailing events that negatively impacted Foghorn Therapeutics' reputation in the past year.
Ownership
Foghorn Therapeutics Inc. has a mixed ownership structure including institutional, retail, and individual investors. Institutional investors hold a significant portion of the stock, with 112 institutional owners holding 41,955,456 shares. Major institutional owners include Flagship Pioneering Inc., Fmr Llc, Bvf Inc/il, Deerfield Management Company, L.p. (series C), Raymond James Financial Inc, BlackRock, Inc., Vanguard Group Inc, Euclidean Capital LLC, Geode Capital Management, Llc, and Siren, L.L.C. Cigall Kadoch is the largest individual shareholder, owning 3.62 million shares, representing 6.41% of the company.
